Abbott Laboratories (NYSE:ABT) shares saw unusually-high trading volume on Thursday . Approximately 23,239,489 shares changed hands during trading, an increase of 163% from the previous session’s volume of 8,819,875 shares.The stock last traded at $43.70 and had previously closed at $43.17.

ABT has been the topic of several analyst reports. Barclays PLC reaffirmed an “overweight” rating and set a $48.00 price target on shares of Abbott Laboratories in a research note on Tuesday, July 12th. Bank of America Corp. reiterated a “buy” rating and set a $50.00 price objective on shares of Abbott Laboratories in a report on Friday, August 12th. Credit Suisse Group AG reiterated a “buy” rating on shares of Abbott Laboratories in a report on Wednesday, June 8th. TheStreet upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a report on Monday. Finally, Jefferies Group increased their price objective on shares of Abbott Laboratories from $49.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, August 4th. Seven equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $47.08.

The stock’s 50 day moving average price is $43.74 and its 200-day moving average price is $40.71. The company has a market cap of $62.97 billion and a P/E ratio of 28.28.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, July 20th. The healthcare product maker reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.53 by $0.02. The business had revenue of $5.30 billion for the quarter, compared to analyst estimates of $5.24 billion. During the same quarter last year, the firm earned $0.52 earnings per share. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. On average, equities analysts anticipate that Abbott Laboratories will post $2.20 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Monday, August 15th. Stockholders of record on Friday, July 15th were issued a dividend of $0.26 per share. The ex-dividend date of this dividend was Wednesday, July 13th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 2.43%.

In other news, insider Stephen R. Fussell sold 41,500 shares of the company’s stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $45.00, for a total transaction of $1,867,500.00. Following the completion of the transaction, the insider now directly owns 196,467 shares in the company, valued at $8,841,015. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Hubert L. Allen sold 3,400 shares of the company’s stock in a transaction that occurred on Tuesday, June 28th. The stock was sold at an average price of $37.14, for a total value of $126,276.00. Following the transaction, the executive vice president now owns 91,857 shares of the company’s stock, valued at $3,411,568.98. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have modified their holdings of ABT. S&T Bank PA boosted its stake in Abbott Laboratories by 0.9% in the fourth quarter. S&T Bank PA now owns 65,676 shares of the healthcare product maker’s stock worth $2,950,000 after buying an additional 591 shares in the last quarter. Girard Partners LTD. boosted its stake in Abbott Laboratories by 1.5% in the fourth quarter. Girard Partners LTD. now owns 44,172 shares of the healthcare product maker’s stock worth $1,984,000 after buying an additional 632 shares in the last quarter. Montag A & Associates Inc. boosted its stake in Abbott Laboratories by 1.7% in the fourth quarter. Montag A & Associates Inc. now owns 64,376 shares of the healthcare product maker’s stock worth $2,891,000 after buying an additional 1,060 shares in the last quarter. Palladium Partners LLC boosted its stake in Abbott Laboratories by 2.7% in the fourth quarter. Palladium Partners LLC now owns 57,738 shares of the healthcare product maker’s stock worth $2,593,000 after buying an additional 1,508 shares in the last quarter. Finally, Genesee Valley Trust Co. boosted its stake in Abbott Laboratories by 2.5% in the fourth quarter. Genesee Valley Trust Co. now owns 64,089 shares of the healthcare product maker’s stock worth $2,878,000 after buying an additional 1,569 shares in the last quarter.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.